Adjuvants Enhance the Induction of Germinal Center and Antibody Secreting Cells in Spleen and Their Persistence in Bone Marrow of Neonatal Mice

Front Immunol. 2019 Sep 26:10:2214. doi: 10.3389/fimmu.2019.02214. eCollection 2019.

Abstract

Immaturity of the immune system contributes to poor vaccine responses in early life. Germinal center (GC) activation is limited due to poorly developed follicular dendritic cells (FDC), causing generation of few antibody-secreting cells (ASCs) with limited survival and transient antibody responses. Herein, we compared the potential of five adjuvants, namely LT-K63, mmCT, MF59, IC31, and alum to overcome limitations of the neonatal immune system and to enhance and prolong responses of neonatal mice to a pneumococcal conjugate vaccine Pnc1-TT. The adjuvants LT-K63, mmCT, MF59, and IC31 significantly enhanced GC formation and FDC maturation in neonatal mice when co-administered with Pnc1-TT. This enhanced GC induction correlated with significantly enhanced vaccine-specific ASCs by LT-K63, mmCT, and MF59 in spleen 14 days after immunization. Furthermore, mmCT, MF59, and IC31 prolonged the induction of vaccine-specific ASCs in spleen and increased their persistence in bone marrow up to 9 weeks after immunization, as previously shown for LT-K63. Accordingly, serum Abs persisted above protective levels against pneumococcal bacteremia and pneumonia. In contrast, alum only enhanced the primary induction of vaccine-specific IgG Abs, which was transient. Our comparative study demonstrated that, in contrast to alum, LT-K63, mmCT, MF59, and IC31 can overcome limitations of the neonatal immune system and enhance both induction and persistence of protective immune response when administered with Pnc1-TT. These adjuvants are promising candidates for early life vaccination.

Keywords: adjuvant; antibody-secreting cell persistence; bone marrow; germinal center; neonate; protective antibodies; spleen; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology*
  • Alum Compounds / pharmacology
  • Animals
  • Animals, Newborn
  • Antibodies, Bacterial / blood
  • Antibody-Producing Cells / drug effects*
  • Bacterial Toxins / pharmacology
  • Bone Marrow / drug effects*
  • Bone Marrow / immunology
  • Cholera Toxin / pharmacology
  • Drug Combinations
  • Enterotoxins / pharmacology
  • Escherichia coli Proteins / pharmacology
  • Germinal Center / drug effects*
  • Immunoglobulin G / blood
  • Mice
  • Oligodeoxyribonucleotides / pharmacology
  • Oligopeptides / pharmacology
  • Pneumococcal Vaccines / administration & dosage
  • Polysorbates / pharmacology
  • Spleen / drug effects*
  • Spleen / immunology
  • Squalene / pharmacology

Substances

  • Adjuvants, Immunologic
  • Alum Compounds
  • Antibodies, Bacterial
  • Bacterial Toxins
  • Drug Combinations
  • Enterotoxins
  • Escherichia coli Proteins
  • IC31 adjuvant
  • Immunoglobulin G
  • MF59 oil emulsion
  • Oligodeoxyribonucleotides
  • Oligopeptides
  • Pneumococcal Vaccines
  • Polysorbates
  • aluminum sulfate
  • Squalene
  • Cholera Toxin
  • heat-labile enterotoxin, E coli